SRR8613800
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.440
- MITOTIC_SPINDLE+0.420
- MYC_TARGETS_V2+0.320
- TGF_BETA_SIGNALING+0.320
- HEDGEHOG_SIGNALING+0.260
- UV_RESPONSE_DN+0.140
- SPERMATOGENESIS+0.130
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.500
- COAGULATION-0.430
- INFLAMMATORY_RESPONSE-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- PROTEIN_SECRETION-0.360
- APOPTOSIS-0.350
- BILE_ACID_METABOLISM-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- COMPLEMENT-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ec882950-7595-4ab7-a8b8-86d1422a948a | — | — | 0.886 |
| 2 | BS_BVSW4GTG | medulloblastoma | — | 0.885 |
| 3 | de19e3c1-3508-4c13-b2cf-7079ee934a55 | — | — | 0.883 |
| 4 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.880 |
| 5 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.879 |
| 6 | SRR8752373 | — | — | 0.873 |
| 7 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.871 |
| 8 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.871 |
| 9 | SRR10899974 | — | — | 0.871 |
| 10 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |